An official website of the United States government.

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

The Potential for Veterinary Antibiotic Use to Cause Glycopeptide Resistance in Human Staphylococcus Aureus

Institutions
St. Georges Hospital
Start date
2003
End date
2008
Objective
The horizontal transfer of vancomycin resistance genes from enterococci to Staphylococcus aureus would be a human medical catastrophe, as we are dependent on this antibiotic to treat hundreds of thousands of human S. aureus (including MRSA) infections in the UK every year. For this reason, avoparcin, a glycopeptide antibiotic related to vancomycin, was banned in the EU. This decision was based on the assumption that horizontal transfer of glycopeptide resistance would be accelerated by the use of this antibiotic. These new super-resistant S. aureus would then spread to humans and to hospitals.

However, there are several confounding issues with this hypothesis. First, S. aureus, unlike most bacteria, actively blocks uptake of foreign genes from other bacteria. Secondly, animal strains of S. aureus are thought to be quite different to human strains, and it is unlikley that they will colonise, and therefore infect, humans in the same way that human strains do. Thirdly, we do not know if resistance can easily be spread from animal S. aureus to human S. aureus strains.

This project will address these issues, providing baseline information that can be used to assess the true risks of antibiotic resistance spreading to clinical S. aureus, and to identify the "red-flag" strains indicating resistance is spreading.

Funding Source
Dept. for Environment, Food and Rural Affairs
Project number
OD2013
Categories
Antimicrobial Resistance
Bacterial Pathogens